BCRX
BioCryst Pharmaceuticals IncNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$2.38B
P/E Ratio
7.83
EPS
$1.21
Beta
0.69
52W High
$11.31
52W Low
$6.00
50-Day MA
$8.03
200-Day MA
$7.87
Dividend Yield
—
Profit Margin
30.20%
Forward P/E
112.36
PEG Ratio
9.39
About BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small molecule drugs. The company is headquartered in Durham, North Carolina.
Fundamentals
| Revenue (TTM) | $874.84M |
| Gross Profit (TTM) | $691.68M |
| EBITDA | $350.79M |
| Operating Margin | 65.60% |
| Return on Equity | -1925.00% |
| Return on Assets | 43.20% |
| Revenue/Share (TTM) | $4.17 |
| Book Value | $-0.56 |
| Price-to-Book | 56.59 |
| Price-to-Sales (TTM) | 2.71 |
| EV/Revenue | 2.775 |
| EV/EBITDA | 6.98 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 209.10% |
| Shares Outstanding | $250.80M |
| Float | $218.18M |
| % Insiders | 1.31% |
| % Institutions | 87.11% |
Analyst Ratings
Consensus ($21.30 target)
3
Strong Buy7
BuyData last updated: 4/7/2026